Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Increases By 48.5%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 1,990,000 shares, a growth of 48.5% from the March 31st total of 1,340,000 shares. Based on an average trading volume of 987,100 shares, the days-to-cover ratio is presently 2.0 days.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They set a “sell” rating on the stock.

Brainstorm Cell Therapeutics Price Performance

Brainstorm Cell Therapeutics stock remained flat at $0.53 during midday trading on Friday. The company had a trading volume of 266,201 shares, compared to its average volume of 977,687. The stock’s fifty day simple moving average is $0.48 and its two-hundred day simple moving average is $0.33. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $3.34.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Monday, April 1st. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Equities analysts expect that Brainstorm Cell Therapeutics will post -0.28 EPS for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.